BlackRock, Inc. 13D and 13G filings for Atara Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Atara Biotherapeutics, Inc. ATRA | BlackRock Inc. BLK | 0 0.000% | -283,489 (Position Closed) | Filing |
| 2024-01-26 5:25 pm Sale | 2023-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA | BlackRock Inc. BLK | 283,489 7.000% | -82,597 (-22.56%) | Filing |
| 2023-01-24 1:56 pm Purchase | 2022-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA | BlackRock Inc. BLK | 366,086 9.600% | 53,424 (+17.09%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA | BlackRock Inc. BLK | 312,662 8.800% | 54,485 (+21.10%) | Filing |
| 2021-01-28 5:56 pm Purchase | 2020-12-31 | 13G | Atara Biotherapeutics, Inc. ATRA | BlackRock Inc. BLK | 258,177 7.800% | 74,960 (+40.91%) | Filing |